Parkinson’s disease may leave a molecular trace in one of the body’s most overlooked fluids: tears. A study by Acera, Gómez-Esteban, Ruiz-Martínez and colleagues, published in npj Parkinson’s Disease, reports that tear proteomics can reveal reproducible, pathway-level signatures associated with Parkinson’s disease pathogenesis. The finding places tears at the center of a rapidly expanding search for non-invasive biological signals of neurodegeneration, offering a possible alternative to approaches that depend on blood, cerebrospinal fluid or expensive brain imaging.
Proteomics is the large-scale study of proteins, the molecules that perform most of the work inside cells. Unlike DNA, which remains relatively stable, proteins change in response to disease, inflammation, cellular stress and altered metabolism. Tears contain more than water and salt: they carry proteins, lipids and signaling molecules produced by the eye and surrounding tissues, as well as components influenced by broader physiological conditions. Because tear collection is quick and generally painless, researchers have increasingly explored whether this fluid can provide a molecular window into disorders that primarily affect the brain.
The importance of the new work lies in its focus on pathways rather than isolated proteins. A single protein can vary because of medication, age, diet, infection or ordinary biological fluctuation. A coordinated pattern involving several proteins, however, may provide a more reliable indication of a disease-related process. Pathway-level analysis groups proteins according to the biological functions in which they participate, such as immune signaling, energy production, protein degradation, synaptic maintenance or cellular stress responses. This approach can transform a long list of molecular measurements into a map of the biological systems being altered.
Parkinson’s disease is best known for the progressive loss or dysfunction of dopamine-producing neurons in a region of the brain called the substantia nigra. That damage disrupts movement and can produce tremor, rigidity, slowness and balance problems. Yet Parkinson’s is not simply a dopamine disorder. Mitochondrial dysfunction, chronic neuroinflammation, impaired lysosomal activity, abnormal protein handling and disturbances in communication between neurons all appear to contribute to its development. The tear signatures described in the study are therefore significant because they may reflect several interconnected processes rather than a single downstream consequence of neuronal loss.
The researchers’ central message is reproducibility. In biomedical research, a promising molecular signal is only useful if it can be detected consistently across samples and, ideally, across independent groups of participants. Tear composition can be affected by eye irritation, dryness, environmental exposure and collection procedures, making consistency especially important. By identifying pathway-level patterns that are reproducible, the study supports the idea that tear proteomics could move beyond an exploratory experiment and become a foundation for future biomarker development.
That does not mean a tear test for Parkinson’s disease is ready for use in clinics. A molecular signature can indicate that biological processes associated with the disease are present without proving that an individual has Parkinson’s. Researchers would still need to determine how accurately the signature separates Parkinson’s from healthy aging and from conditions with overlapping symptoms, including atypical parkinsonian disorders, Alzheimer’s disease and other neurological diseases. The influence of medication, disease stage, sex, age, eye health and other medical conditions would also have to be carefully measured.
The potential impact, however, is substantial. Current diagnosis is largely clinical, based on a patient’s symptoms, neurological examination and response to treatment. There is no universally used blood or tear test that can definitively identify Parkinson’s disease before symptoms become obvious. An accessible molecular assay could help researchers identify biological subtypes, monitor progression or evaluate whether an experimental therapy is changing disease-related pathways. It might also support earlier investigation, at a stage when neurons are damaged but not yet irreversibly lost.
The study also illustrates a broader shift in neuroscience: researchers are looking for peripheral signals that mirror events deep inside the brain. Tears cannot provide a direct sample of neurons in the substantia nigra, but they may capture systemic responses to neurodegeneration or molecular pathways shared between ocular tissues and the nervous system. The eye is closely connected to the brain through neural, vascular and immune networks, and several neurological disorders have already been investigated through ocular tissues and fluids. Tear proteomics could therefore become part of a larger “liquid biopsy” strategy for brain disease.
For now, the most important result is not a single diagnostic molecule but the evidence that tear proteins can form stable, biologically meaningful patterns linked to Parkinson’s disease pathogenesis. The work will need validation in larger and more diverse populations, along with standardized tear-collection methods and independent laboratory testing. If those steps confirm the findings, a sample collected with a tiny strip of absorbent paper could eventually help scientists read the molecular story of Parkinson’s disease—turning an ordinary tear into a potential tool for earlier detection, more precise research and better-targeted treatment.
Subject of Research: Tear proteomics and reproducible pathway-level molecular signatures associated with Parkinson’s disease pathogenesis.
Article Title: Tear proteomics reveals reproducible pathway-level signatures of Parkinson’s disease pathogenesis.
Article References: Acera, A., Gómez-Esteban, J., Ruiz-Martínez, J. et al. “Tear proteomics reveals reproducible pathway-level signatures of Parkinson’s disease pathogenesis.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01504-7
Image Credits: AI Generated
DOI: 10.1038/s41531-026-01504-7
Keywords: Parkinson’s disease, tear proteomics, neurodegeneration, biomarkers, proteomics, pathway signatures, non-invasive diagnostics
